Advertisement

Nuclea Biotechnologies Inc., which is developing tests for various kinds of cancers as well as diabetes, has closed its first Series C funding round of $5 million to support clinical trials and new hires related to the development of its fatty acid synthase tests for prostate and breast cancers.

Advertisement
Advertisement